HER2-positive breast cancer patients generally benefit from neoadjuvant chemotherapy in the form of anthracyclines and taxanes with a higher complete pathological response in comparison with luminal and triple-negative subtypes [80]. Here, ERBB2 is linked to breast carcinoma.